Makers of drug-device combination products are urged to anticipate postapproval changes that they may wish to make and to develop plans for the preparation of revision proposals, new FDA draft guidance says.<p>Source: <a href=""></a></p><p><a href="">Medical Diagnostics</a> <a href="">Diagnostics Letter</a> <a href="">Drug GMP Report</a> <a href="">Capitol Hill and at the FDA</a> <a href="">medical equipment</a> </p>

Leave a Reply